We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

22 hedge funds and large institutions have $3.93M invested in BRAINSTORM CELL THERAPUTC in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less capital invested

Capital invested by funds: $4.52M → $3.93M (-$594K)

21% less funds holding

Funds holding: 28 → 22 (-6)

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
22
Holders Change
-6
Holders Change %
-21.43%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$23.5K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.5K
3
UBS Group
UBS Group
Switzerland
+$12.6K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$60K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$50K
3
SM
Sabby Management
Florida
-$38.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$32K
5
LPL Financial
LPL Financial
California
-$27K

BCLI Hedge Fund Activity: Q2 2016 in Review

22 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2016, worth a combined $3.93M — down 13% from $4.52M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BCLI and 3 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Bank of America, opening a new position worth an estimated $23.5K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $60K sold.

  • 22 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2016, down from 28 in Q1 2016.
  • Funds reported $3.93M of BRAINSTORM CELL THERAPUTC stock for Q2 2016, down 13% quarter-over-quarter.
  • 3 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2016 and 9 closed out, a net change of -6 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2016 was Bank of America, an estimated $23.5K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q2 2016 was A.R.T. Advisors, an estimated $60K sold.

Based on aggregated 13F filings for Q2 2016.